ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients

Pharmacogenomics

Volumn 11, Issue 12, 2010, Pages 1715-1723

  Gonzalez Haba, Eva ^a   García, Maria I ^a   Cortejoso, Lucia ^a   López Lillo, Carolina ^a   Barrueco, Nélida ^a   García Alfonso, Pilar ^a   Alvarez, Sonsoles ^a   Jiménez, Jose L ^a   Martín, María L ^a   Muñóz Fernández, Maria A ^a   Sanjurjo, María ^a   Lpez Fernández, Luis A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

5 fluorouracil; adverse reactions capecitabine; ATP binding cassette B1; pharmacogenetics

Indexed keywords

ADENOSINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOSINE; FLUOROPYRIMIDINE; FLUOROURACIL; GUANOSINE; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; THYMINE;

ADULT; AGED; ARTICLE; ASTHENIA; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; PHARMACOGENETICS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 78650316625     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.159     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
2. Van Cutsem E, Twelves C, Cassidy J et al.: Oral capecitabine compared with intravenous fuorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001).
3. Bhushan S, Mcleod H, Walko CM: Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin. Colorectal Cancer 8(1), 15-21 (2009).
4. Schwab M, Zanger UM, Marx C et al.: Role of genetic and nongenetic factors for fuorouracil treatment-related severe toxicity: A prospective clinical trial by the german 5-FU toxicity study group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
5. Romsicki Y, Sharom FJ: The atpase and ATP-binding functions of p-glycoprotein - modulation by interaction with defned phospholipids. Eur. J. Biochem. 256(1), 170-178 (1998).
6. Sai K, Kaniwa N, Itoda M et al.: Haplotype ana lysis of ABCB1/MDR1 blocks in a japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13(12), 741-757 (2003).
7. Kim RB, Leake BF, Choo EF et al.: Identifcation of functionally variant MDR1 alleles among european americans and african Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
8. Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M: ABCB1 gene polymorphisms and haplotype ana lysis in colorectal cancer. Int. J. Colorectal Dis 24(8), 895-905 (2009).
9. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR: ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 8, 50 (2008).
10. De Iudicibus S, De Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G: ABCB1 gene polymorphisms and expression of p-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res. 28(6B), 3921-3928 (2008).
11. Glimelius B, Garmo H, Berglund A et al.: Prediction of irinotecan and 5-fuorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. (2010) (Epub ahead of print).
12. Heo YS, Chang HM, Kim TW et al.: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J. Clin. Pharmacol. 44(10), 1166-1172 (2004).
13. Skof E, Rebersek M, Hlebanja Z, Ocvirk J: Capecitabine plus irinotecan (xeliri regimen) compared with 5-FU/lv plus irinotecan (folfri regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase ii trial. BMC Cancer 9, 120 (2009).
14. Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S: Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr. Oncol. 16(6), 13-20 (2009).
15. Han JY, Lim HS, Yoo YK et al.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced nonsmall cell lung cancer. Cancer 110(1), 138-147 (2007).
16. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette c transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fuorouracil-resistant cells. Pancreatology 9(1-2), 136-144 (2009).
17. Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z: Role of BCRP as a biomarker for predicting resistance to 5-fuorouracil in breast cancer. Cancer. Chemother. Pharmacol. 63(6), 1103-1110 (2009).
18. Braun MS, Richman SD, Thompson L et al.: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The focus trial. J. Clin. Oncol. 27(33), 5519-5528 (2009).
19. Braun MS, Richman SD, Quirke P et al.: Predictive biomarkers of chemotherapy effcacy in colorectal cancer: results from the UK MRC focus trial. J. Clin. Oncol. 26(16), 2690-2698 (2008).
20. Chang H, Rha SY, Jeung HC et al.: Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1), 271-278 (2010).
21. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
22. Morel A, Boisdron-Celle M, Fey L et al.: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fuorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006).